CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR 2017; 01(02): 089-095
DOI: 10.1055/s-0037-1603196
Review Article
Indian Society of Vascular and Interventional Radiology

Expanding Role of Endovascular Repair for Type B Aortic Dissection

Sanjiv Sharma
1   Department of Cardiovascular Radiology and Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, India
,
Arun Sharma
1   Department of Cardiovascular Radiology and Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
Further Information

Address for correspondence

Sanjiv Sharma, MD
Department of Cardiovascular Radiology and Endovascular Interventions
All India Institute of Medical Sciences, New Delhi
India   

Publication History

Publication Date:
28 July 2017 (online)

 

Abstract

Aortic dissection is a medical emergency that can quickly lead to death, despite optimal treatment. The Stanford classification is widely used and is in close relationship to clinical practice, as type A dissections require primary surgical repair whereas type B dissections are treated medically as initial treatment with surgery or endovascular repair (EVR) reserved for any complications. Multislice CT is the investigation of choice to establish the diagnosis and plan treatment strategies. Therapeutic strategies differ for treatment of an acute dissection compared with a chronic dissection. Traditionally, most institutions favor a “complication specific” approach for type B dissection with antihypertensive treatment and use of β-blockers as primary therapy. Surgery or EVR is reserved for patients with recurrent pain, life-threatening complications, or rapid aortic expansion. With above algorithms, there is evidence that 30 to 50% patients on conservative therapy develop serious morbidity or mortality over 5-year period. Clinical and imaging markers of adverse outcome are being identified to revise the management strategies and offer EVR to those at risk for adverse outcome. This is especially relevant in view of the fact that EVR for type B dissection is associated with procedural success in 99.2 ± 0.1% patients. Overall survival rates of 96.9% at 30 days, 96.7% at 6 months, 96.4% at 1 year, 95.6% at 2 years, and 95.2% at 5 years are reported after EVR in type B dissections. There is emerging evidence that EVR may be noninferior to surgery in this group of patients. These observations along with the development of dissection-specific device designs have the potential to rewrite the management algorithms for type B aortic dissection and define the role of EVR in this disease.


#

Introduction

Aortic dissection (AD) is characterized by a tear in the intima that allows pulsatile blood to penetrate the vessel wall. The entry tear is commonly located within the first 2 cm of the ascending aorta or at the isthmus of the aorta just beyond the ligamentum arteriosum as these regions are subjected to the greatest hemodynamic stress. Moreover, tears at these locations are more likely to be transverse in orientation rather than longitudinal. The dissection may propagate in an ante- or retrograde direction or in both directions.[1] [2] [3] It is one of the most catastrophic events that can affect the aorta and is one of the two conditions in which the aorta grows very rapidly over a short time.[1] [4] The mortality rate in patients with untreated acute AD increases by 1%/h, with 13% of patients dying by 12 hours, 21% by 24 hours, and approximately 80% are dead within 2 weeks, if untreated and located in the ascending aorta.[1] [2] [3] [4] [5] It is approximately two to three times more common than a ruptured abdominal aortic aneurysm.


#

Classification Systems

Various methods have been used to describe ADs. The systems commonly in use are based on either the anatomy of the dissection or the duration of onset of symptoms prior to presentation.[6] The Stanford classification divides dissections into two types depending on whether the ascending aorta is involved: type A involves the ascending aorta whereas type B involves the descending aorta distal to the left subclavian artery. The DeBakey classification divides dissections into three types based on where the original intimal tear is located and the extent of the dissection:

  • Type I involves the ascending aorta, aortic arch, and descending aorta.

  • Type II is confined to the ascending aorta.

  • Type III is confined to the descending aorta distal to the left subclavian artery.

Type III dissections are further divided into IIIa and IIIb: type IIIa refers to dissections that originate distal to the left subclavian artery but extend proximally and/or distally, mostly above the diaphragm; and type IIIb refers to dissections that originate distal to the left subclavian artery, extend only distally, and may extend below the diaphragm. Svensson classification is more etiology and image morphology based, and it divides this group of abnormalities into five classes ([Table 1]).

Table 1

Svensson classification

Class 1: Classic dissection with true and false lumen

Class 2: Intramural hematoma or hemorrhage

Class 3: Subtle dissection without hematoma

Class 4: Atherosclerotic penetrating ulcer

Class 5: Iatrogenic or traumatic dissection

The Stanford classification is in close relationship to clinical practice, as type A dissections require primary surgical repair whereas type B dissections are treated medically as initial treatment with surgery or EVR reserved for any complications.

Typically, AD is seen in the 50- to 70-year age group and is twice as common in men. Nearly 72 to 80% patients have associated hypertension. Connective tissue disorders, vasculitis, trauma, bicuspid aortic valve, and tertiary syphilis are among other less common causes of AD ([Table 2]). In young women, over one-half of the cases are seen during pregnancy, typically in the third trimester or in the postpartum period.[7] Type B dissection accounts for approximately 40% of all dissections and typically occurs in the morning period, more commonly in winters.[8] The clinical diagnosis is often difficult to establish as the symptoms can mimic a variety of diseases, including myocardial infarction and pericarditis, among others.

Table 2

Causes of aortic dissection

Hypertension: 72–80% patients have associated hypertension

Connective tissue disorders

Marfan's syndrome, Turner's syndrome, pseudoxanthoma elasticum

Vasculitis

Trauma: accidental or iatrogenic

Late sequelae of cardiac surgery, esp. after aortic valve replacement for aortic regurgitation

Bicuspid aortic valve

Tertiary syphilis


#

Imaging

Some form of imaging is usually necessary to establish the diagnosis, define the extent of dissection and involvement of branch vessels, and identify the complications. The selection of the imaging technique is usually based on the pretest likelihood of the diagnosis, availability of the testing modality, patient stability, and sensitivity and specificity of the test. Multislice computed tomography (CT) is fast emerging as the investigation of choice to establish the diagnosis and plan treatment strategies in AD.[9] [10] It is preferred over other imaging techniques due to its speed, reproducibility, high spatial and contrast resolution, and its orthogonal potential (ability to provide the best anatomic plane for sizing of proximal and distal neck and landing zones). However, two issues, including the radiation dose and its potential for nephrotoxicity, should be kept in mind while using this technique as these patients will often need a catheter angiography and endovascular treatment in the immediate period and many imaging studies during follow up. Usually, a dual-phase CT angiography (CTA) is recommended in the preoperative evaluation. A typical protocol should include imaging before and after administration of contrast in the arterial phase. Imaging in postcontrast delayed phase is not always required in the preoperative period but must always be done in the follow-up after endovascular treatment to detect the endoleaks. Magnetic resonance imaging (MRI) can also be used for establishing the diagnosis, but it is less reliable in terms of measurements for device sizing for endovascular repair (EVR). We use duplex ultrasound for the evaluation and measurement of the access vessels in the groin.

The following pertinent issues must be kept in mind during imaging interpretation before deciding upon optimal treatment strategy: influence of inherent level of resolution of current imaging technologies on size assessment, the relevance of inclusion or exclusion of the aortic wall in the measurement of the device and sac size, the limitations of specific imaging modalities in terms of profiling the various anatomic segments of the aorta, the influence of geometric complexity of the aorta on the diagnosis and device sizing, the accuracy of comparison of serial images showing 1- to 2-mm change in size over two studies, changes in the shape of the aorta as a marker of disease, the detection of disease activity and its influence on the sac diameters, variations in the aortic diameter during systole and diastole and their impact on size measurements, and factoring in the body surface area while relating aortic size to the hinge points.[6] [9] [10] [11]

The CT images should be analyzed to identify the length of the normal aortic tissue above and below the false channel aneurysm (at least 1.5–2 cm length of normal aorta devoid of any branches above and below the intended site of device delivery should be available for EVR to succeed), the relation of the dissection and false channel aneurysm to the branch vessels, obstructions of the aortic branch vessels (fixed vs. dynamic), and the amount of calcium and thrombus in the diseased segment. At least one common iliac artery should be preferably free of dissection for use as the access vessel for successful EVR. It is also important to ensure that adequate diameter vascular access (external iliac or common femoral artery of > 7.5 mm diameter) free of dissection, extreme tortuosity, extensive calcification, and obstructive disease is available for device delivery.


#

Treatment

In an acute dissection (within the first 2 weeks of the appearance of symptoms), the treatment choice depends on its location. For Stanford type A dissection, surgical management is preferred. For uncomplicated Stanford type B dissections, medical management is preferred in the initial period. The risk of death due to dissection is highest in the first few hours after the dissection begins and decreases afterward. As a result, the therapeutic strategies differ for treatment of an acute dissection compared with a chronic dissection. If the patient survives this period, the prognosis is improved. Approximately, two-thirds of all dissections present in the acute phase.[12] The patients who present 2 weeks after the onset of dissection are said to have chronic ADs. These individuals have been self-selected as survivors of the acute episode and can be treated with medical therapy as long as they are stable and free of complications. Complicated type B dissections can be treated by surgery or EVR.[13] [14] [15] [16] [17] [18]

EVR for type B dissection was first described by Dake et al in 1994.[19] The basic purpose of using stent grafts is to completely cover the primary entry tear and eliminate most of the inflow to the false lumen, thus promoting thrombosis of the false lumen. The graft serves to exclude flow through the initial tear in the intima and redirect aortic blood flow exclusively into the true lumen, reestablishing perfusion of aortic branches affected by the spreading dissection. This can also avoid a true lumen collapse. Procedural success during EVR for type B AD is reported in 99.2 ± 0.1% of patients.[20] In one large recent meta-analysis, major complications were reported in 3.4 ± 0.1% patients, with the most severe neurologic complications in 0.6% patients.[20] Periprocedural stroke was encountered more frequently than paraplegia (0.2 vs. 0%). The overall 30-day mortality was 2.6 ± 0.1%. In addition, 1.5 ± 0.1% of the patients died over a mean follow-up period of 27.1 ± 17.5 months. Life-table analysis yielded overall survival rates of 96.9% at 30 days, 96.7% at 6 months, 96.4% at 1 year, 95.6% at 2 years, and 95.2% at 5 years.[20]

The concept of EVR was also propelled by the desire to induce aortic remodeling by sealing the proximal entry tear, at the same time avoiding the risks associated with open surgery. This rationale was originally based on the clinical observation that patients with spontaneous thrombosis of the false lumen have a better long-term prognosis than those without. Conversely, persistent perfusion of the false lumen has been identified as an independent predictor of progressive aortic enlargement and adverse long-term outcome. Nevertheless, spontaneous thrombosis of the false lumen is a rare observation (< 4% of patients) and most often requires interventions to exclude it from the true lumen. It is unclear whether thrombosis of the false lumen and stabilization of the aortic diameter translates into long-term prevention of aortic rupture.

With better understanding of follow-up outcomes of medical therapy in type B dissection, it is emerging that nearly 50% of patients who are discharged from hospitals after medical treatment present with complications in the following years, and the mortality in 3 to 5 years can reach 20 to 50%, respectively.[3] [21] Moreover, the surgical treatment of aortic complications after medical therapy also carries high mortality. In this setting, EVR has evolved as a promising option, providing a less invasive alternative treatment for type B AD. Studies have shown a mortality rate of < 10% and > 80% success rate of occlusion and thrombosis of the false lumen with EVR.[22] The establishment of the International Registry of Acute Aortic Dissection (IRAD) in 1996, which gathers information from 24 centers in 11 countries, has helped in the development of an understanding of the complexity of AD.[3] At present, the AD-referral centers routinely advocate EVR for complicated type B dissection, as acceptable early and midterm results have shown that there is adequate prevention of aneurysm rupture.[23] [24] [25] [26]

Better understanding of clinical and imaging markers has helped identify patients with uncomplicated type B dissection who are at increased risk for worse prognosis and may benefit from an early endovascular or surgical repair. In the setting of type B dissection, clinical markers ([Table 3]) such as recurrent and refractory pain, refractory hypertension, age > 60 years, white race, Marfan's syndrome, and fibrinogen-fibrin degradation product level of 20 mg/mL at admission are associated with an adverse outcome.[27] [28] [29] [30] [31] Moreover, several imaging markers can also be used to identify high-risk patients. These may include an aortic diameter of > 44 mm at diagnosis, partial false lumen thrombosis, false lumen diameter of > 22 mm (100% sensitive, 76% specific), location of primary entry tear on the under surface of the arch or on its medial aspect, width of entry tear > 10 mm, elliptical shape of true lumen, circular false lumen, cross-sectional area of false lumen to true lumen of > 0.7, and a spiral configuration of the dissection ([Table 3]).[32] [33] [34] [35] [36] [37]

Table 3

Clinical and radiologic markers of adverse outcome in type B aortic dissection

Clinical/Laboratory

Radiologic

Recurrent and refractory pain

Total aortic diameter > 44 mm

Refractory hypertension

Absolute FL diameter > 22 mm

(100% sensitive, 76% specific)

Age > 60 y

Cross-sectional area of FL/total lumen > 0.7

White race

Width of entry tear > 10 mm

Marfan's syndrome

Location of primary entry tear—under surface of arch or medial

Fibrinogen-fibrin degradation product level of 20 mg/mL at admission

Elliptical shape of TL in combination with circular FL/spiral configuration of dissection flap

Abbreviations: FL, false lumen; TL, true lumen.


Dissection is classified as complicated ([Table 4]) if it is associated with refractory pain; malperfusion; rupture, free, or contained; hypertension that is associated with malperfusion or persistent despite full medical therapy; increase in periaortic hematoma; and hemorrhagic pleural effusion in two CT examinations, suggesting an impending rupture.[38] [39] Moreover, refractory pain and persistent hypertension are associated with an increased mortality.[40]

Table 4

Complicated type B aortic dissection

Rupture-free/contained

Malperfusion—impending organ failure

Hypertension when associated with malperfusion or persistent despite full medical therapy

Increase in periaortic hematoma

Hemorrhagic pleural effusion in two CTs s/o impending rupture

Refractory pain—may be indicative of malperfusion

Abbreviation: CT, computed tomography.


The EUROSTAR (EUROpean collaborators on Stent/graft Techniques for aortic Aneurysm Repair) registry in 2004 described the first large case series of patients treated with EVR and demonstrated primary technical success of 89%, 30-day mortality of 6.5%, 1-year survival of 90%, and paraplegia in 0.8%.[41]

Fattori et al published data from 1995 to 2012 from the IRAD in which 1,129 consecutive patients with type B acute AD were monitored.[42] Uncomplicated patients were medically treated (75.6%) and those with complicated dissection were indicated for EVR (24.4%). The hospital mortality between the two groups was similar, but at a 5-year follow-up the group that underwent EVR had a lower mortality of 15.5% compared with 29% in patients who were medically treated. Moreover, conclusions drawn from other studies also suggested that EVR is safe, effective, and improves aortic remodeling in suitable patients with type B dissection ([Tables 5], [6]).[43] [44] [45]

Table 5

Comparison of TEVAR versus medical therapy in type B aortic dissection

Author (y)

No. of patients

Subclassification

Early mortality

(%)

Early CVA

n (%)

Early SCI

n (%)

Mean follow-up

(mo)

Survival rate (%)

Fattori et al, IRAD[39] TEVAR (2008)

43

Acute complicated

11.6

NA 1 (2.3)

2.3 y median

On 27 patients

1 y (88.9)

3 y(76.2)

Fattori et al, IRAD[39] Medical (2008)

390

Acute

8.7

NA

2.3 y median

On 189 patients

1 y (90.3)

3 y (77.6)

Garbade et al,[45] TEVAR (2010)

46

27 acute complicated

19 acute uncomplicated

19.6

11 (23.9)

1,107 d

1 y (80)

3 y (73.3)

5 y (56.3)

Garbade et al,[45] Medical (2010)

84

63 acute uncomplicated

21 acute complicated

8.3

12 (14.3)

1,107 d

1 y (86.2)

3 y (80.9)

5 y (72.1)

Abbreviations: CVA, cerebrovascular accidents; IRAD, international registry of acute aortic dissection; NA, not available; SCI, spinal cord ischemia; TEVAR, thoracic endovascular aortic repair.


Table 6

Comparison of TEVAR versus open surgery in type B aortic dissection

Author (y)

No. of patients

Subclassification

Early mortality

n (%)

Early CVA

n (%)

Early SCI

n (%)

Mean follow-up

(mo)

Survival rate (%)

Fattori et al,[39] TEVAR (2008)

43

Acute complicated

5 (11.6)

NA

1 (2.3)

2.3 y median

> 29 patients:

1 y(88.9)

3 y(76.2)

Fattori et al,[39] Open (2008)

59

Acute complicated

20 (33.9)

4(6.8)

3 (5.1)

NA

NA

Zeeshan et al,[43] TEVAR (2010)

45

Acute complicated

2 (4.4)

3(6.7)

6 (13.3)

37 (2 mo–7 y)

1 y(82)

5 y(79)

Zeeshan et al,[43] Open (2010)

20

Acute complicated

8 (40.0)

0

2 (10)

37 (2 mo–7 y)

1 y(58)

3 y(52)

5 y(44)

Abbreviations: CVA, cerebrovascular accidents; NA, not available; SCI, spinal cord ischemia; TEVAR, thoracic endovascular aortic repair.


INSTEAD (INvestigation of STEnt Grafts in Aortic Dissection) XL trial showed that EVR in addition to optimal medical treatment is associated with improved 5-year aorta-specific survival and delayed disease progression and suggested that EVR should be considered in stable type B dissection with suitable anatomy to improve late outcome.[24] Recently, ADSORB (Acute Dissection: Stent graft OR Best medical therapy) trial compared the outcomes of a group of patients with uncomplicated dissection randomized to either best medical treatment or best medical therapy with EVR. The results suggested that the remodeling with thrombosis of the false lumen and reduction in its diameter is induced by EVR, concluding that EVR may be a safe alternative to treat acute uncomplicated dissection.[46]

VIRTUE registry described the mid-term clinical and morphologic results of EVR in patients with type B dissection. Findings suggested similar aortic remodeling in subacute stages as in the acute group. This retention of aortic plasticity in the subacute group further lengthens the therapeutic window for the treatment of uncomplicated type B dissection.[47]

The premature occlusion of the false lumen entrance seems to improve the prognosis of patients in the long term. Studies have suggested that the patency of the false lumen remains an independent risk factor for death or events related to the dissection.[48] The mortality associated with dissection is nearly 5.6 times lower in patients with thrombosed false sac on medical treatment than in the group of patients in whom the false lumen remained patent. Recently published data from various trials ([Table 7]) suggest that thrombosis of the false lumen and stabilization of the aortic diameter translate into long-term prevention of aortic rupture.

Table 7

Outcomes of trials/registries in type B aortic dissection

Trial/

Registry

Subclassification

Aorta specific 5-y mortality rate

FL/TL/total lumen

(mm)

30-d mortality

(%)

Mean follow-up

(y)

Survival rate

Other Comments

INSTEAD XL trial[24]

Uncomplicated beyond acute phase

EVAR + OMT- 6.9%

OMT-19.3%

NA

2

EVAR + OMT-28.1%

OMT-4.1%

NA

ADSORB trial[46]

Acute uncomplicated

NA

BMT + EVAR (1 y)

18.5/32.2/38.8

BMT (1 y)

25.1/25.5/42.1

1

NA

NA

VIRTUE registry[47]

Acute

Subacute

Chronic (complicated)

NA

Acute-8

Subacute-0

Chronic-0

3

NA

Acute and subacute: greater reduction in FL area than chronic group

Acute and subacute: consistent reduction in FL area

Chronic group: overall increase in FL area

Abbreviations: ADSORB, Acute Dissection: Stent graft OR Best medical therapy; BMT, best medical treatment; EVAR, endovascular aortic repair; FL, false lumen; INSTEAD, INvestigation of STEnt Grafts in Aortic Dissection; NA, not available; OMT, optimal medical treatment; TL, true lumen.



#

Conclusion

Overall, there is reasonable consensus that acute type A dissections should be treated by surgery and that uncomplicated type B dissections should be treated with optimized medical therapy. Complicated acute type B dissections should be offered treatment by EVR in suitable patients. Surgery may be reserved for those in whom EVR is not feasible, fails, or results in a complication. Strategies for managing chronic complicated type B dissections are less clear. EVR has shown lower mortality rates, lower incidence of complications related to the aorta, and lower disease progression. There is evidence that EVR may be noninferior to surgery in this group of patients. Clinical and imaging markers are emerging to identify patients with uncomplicated chronic type B dissection who may have an adverse outcome following medical therapy. Current devices used for EVR are not designed for the treatment of AD and have major limitations in terms of addressing the requirements for optimal treatment goals. Overall, device designs and management algorithms in these patients are still evolving. More validated clinical data are necessary to define the role of EVR in the management of type B aortic dissections.


#
#

No conflict of interest has been declared by the author(s).

  • References

  • 1 Elefteriades JA, Rizzo JA. Epidemiology, prevalence, incidence, trends. In: Elefteriades JA. , ed. Acute Aortic Disease. New York, NY: Informa Healthcare; 2008: 89-98
  • 2 Mehta RH, Bossone E, Evangelista A. , et al; International Registry of Acute Aortic Dissection Investigators. Acute type B aortic dissection in elderly patients: clinical features, outcomes, and simple risk stratification rule. Ann Thorac Surg 2004; 77 (05) 1622-1628 , discussion 1629
  • 3 Hagan PG, Nienaber CA, Isselbacher EM. , et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000; 283 (07) 897-903
  • 4 Cerna M, Kocher M, Thomas RP. Acute aorta, overview of acute CT findings and endovascular treatment options. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161 (01) 14-23
  • 5 Erbel R, Alfonso F, Boileau C. , et al; Task Force on Aortic Dissection, European Society of Cardiology. Diagnosis and management of aortic dissection. Eur Heart J 2001; 22 (18) 1642-1681
  • 6 Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55 (09) 841-857
  • 7 Yuan SM. Postpartum aortic dissection. Taiwan J Obstet Gynecol 2013; 52 (03) 318-322
  • 8 Manfredini R, Boari B, Gallerani M. , et al. Chronobiology of rupture and dissection of aortic aneurysms. J Vasc Surg 2004; 40 (02) 382-388
  • 9 Muhs BE, Vincken KL, van Prehn J. , et al. Dynamic cine-CT angiography for the evaluation of the thoracic aorta; insight in dynamic changes with implications for thoracic endograft treatment. Eur J Vasc Endovasc Surg 2006; 32 (05) 532-536
  • 10 Ueda T, Fleischmann D, Rubin GD, Dake MD, Sze DY. Imaging of the thoracic aorta before and after stent-graft repair of aneurysms and dissections. Semin Thorac Cardiovasc Surg 2008; 20 (04) 348-357
  • 11 Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part II: therapeutic management and follow-up. Circulation 2003; 108 (06) 772-778
  • 12 Criado FJ. Aortic dissection: a 250-year perspective. Tex Heart Inst J 2011; 38 (06) 694-700
  • 13 Onitsuka S, Akashi H, Tayama K. , et al. Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. Ann Thorac Surg 2004; 78 (04) 1268-1273
  • 14 Akin I, Kische S, Ince H, Nienaber CA. Indication, timing and results of endovascular treatment of type B dissection. Eur J Vasc Endovasc Surg 2009; 37 (03) 289-296
  • 15 Schneider AJ. Assessment of risk factors and surgical outcome. Surg Clin North Am 1983; 63 (05) 1113-1126
  • 16 Feldman M, Shah M, Elefteriades JA. Medical management of acute type A aortic dissection. Ann Thorac Cardiovasc Surg 2009; 15 (05) 286-293
  • 17 Walsh SR, Tang TY, Sadat U. , et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg 2008; 47 (05) 1094-1098
  • 18 Coady MA, Rizzo JA, Hammond GL, Kopf GS, Elefteriades JA. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg 1999; 67 (06) 1922-1926 , discussion 1953–1958
  • 19 Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med 1994; 331 (26) 1729-1734
  • 20 Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft placement in patients with type B aortic dissection: a meta-analysis in China. J Thorac Cardiovasc Surg 2009; 138 (04) 865-872
  • 21 Fann JI, Smith JA, Miller DC. , et al. Surgical management of aortic dissection during a 30-year period. Circulation 1995; 92 (9, Suppl): II113-II121
  • 22 Duarte JJ, Pontes JC, Benfatti RA, Ferrachini AL, Karakhanian WK, Razuk Filho A. Indication of endovascular treatment of type B aortic dissection—literature review. Rev Bras Cir Cardiovasc 2014; 29 (03) 396-401
  • 23 Jonker FH, Trimarchi S, Verhagen HJ, Moll FL, Sumpio BE, Muhs BE. Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. J Vasc Surg 2010; 51 (04) 1026-1032 , 1032.e1–1032.e2
  • 24 Nienaber CA, Rousseau H, Eggebrecht H. , et al; INSTEAD Trial. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation 2009; 120 (25) 2519-2528
  • 25 Parsa CJ, Schroder JN, Daneshmand MA, McCann RL, Hughes GC. Midterm results for endovascular repair of complicated acute and chronic type B aortic dissection. Ann Thorac Surg 2010; 89 (01) 97-102 , discussion 102–104
  • 26 Eggebrecht H, Nienaber CA, Neuhäuser M. , et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. Eur Heart J 2006; 27 (04) 489-498
  • 27 Evangelista A, Salas A, Ribera A. , et al. Long-term outcome of aortic dissection with patent false lumen: predictive role of entry tear size and location. Circulation 2012; 125 (25) 3133-3141
  • 28 Kitada S, Akutsu K, Tamori Y, Yoshimuta T, Hashimoto H, Takeshita S. Usefulness of fibrinogen/fibrin degradation product to predict poor one-year outcome of medically treated patients with acute type B aortic dissection. Am J Cardiol 2008; 101 (09) 1341-1344
  • 29 Luebke T, Brunkwall J, Type B. Type B aortic dissection: a review of prognostic factors and meta-analysis of treatment options. Aorta (Stamford) 2014; 2 (06) 265-278
  • 30 Jonker FH, Trimarchi S, Rampoldi V. , et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic expansion after acute type B aortic dissection. Ann Thorac Surg 2012; 94 (04) 1223-1229
  • 31 Tolenaar JL, van Keulen JW, Jonker FH. , et al. Morphologic predictors of aortic dilatation in type B aortic dissection. J Vasc Surg 2013; 58 (05) 1220-1225
  • 32 Clough RE, Albayati MA, Donati T, Taylor PR. Uncomplicated type B dissections: which patients should be treated? Lessons learned from the recent literature. J Cardiovasc Surg (Torino) 2014; 55 (02) (Suppl. 01) 145-150
  • 33 Grommes J, Greiner A, Bendermacher B. , et al. Risk factors for mortality and failure of conservative treatment after aortic type B dissection. J Thorac Cardiovasc Surg 2014; 148 (05) 2155-2160.e1
  • 34 Tsai TT, Evangelista A, Nienaber CA. , et al; International Registry of Acute Aortic Dissection. Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med 2007; 357 (04) 349-359
  • 35 Song JM, Kim SD, Kim JH. , et al. Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection. J Am Coll Cardiol 2007; 50 (08) 799-804
  • 36 Loewe C, Czerny M, Sodeck GH. , et al. A new mechanism by which an acute type B aortic dissection is primarily complicated, becomes complicated, or remains uncomplicated. Ann Thorac Surg 2012; 93 (04) 1215-1222
  • 37 Kitamura T, Torii S, Oka N. , et al. Key success factors for thoracic endovascular aortic repair for non-acute Stanford type B aortic dissection. Eur J Cardiothorac Surg 2014; 46 (03) 432-437 , discussion 437
  • 38 Fattori R, Cao P, De Rango P. , et al. Interdisciplinary expert consensus document on management of type B aortic dissection. J Am Coll Cardiol 2013; 61 (16) 1661-1678
  • 39 Fattori R, Tsai TT, Myrmel T. , et al. Complicated acute type B dissection: is surgery still the best option? A report from the International Registry of Acute Aortic Dissection. JACC Cardiovasc Interv 2008; 1 (04) 395-402
  • 40 Trimarchi S, Eagle KA, Nienaber CA. , et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Importance of refractory pain and hypertension in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2010; 122 (13) 1283-1289
  • 41 Leurs LJ, Bell R, Degrieck Y, Thomas S, Hobo R, Lundbom J. ; EUROSTAR; UK Thoracic Endograft Registry collaborators. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. J Vasc Surg 2004; 40 (04) 670-679 , discussion 679–680
  • 42 Fattori R, Montgomery D, Lovato L. , et al. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc Interv 2013; 6 (08) 876-882
  • 43 Zeeshan A, Woo EY, Bavaria JE. , et al. Thoracic endovascular aortic repair for acute complicated type B aortic dissection: superiority relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg 2010; 140 (6, Suppl): S109-S115 , discussion S142–S146
  • 44 Nienaber CA, Kische S, Rousseau H. , et al; INSTEAD-XL trial. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013; 6 (04) 407-416
  • 45 Garbade J, Jenniches M, Borger MA. , et al. Outcome of patients suffering from acute type B aortic dissection: a retrospective single-centre analysis of 135 consecutive patients. Eur J Cardiothorac Surg 2010; 38 (03) 285-292
  • 46 Brunkwall J, Kasprzak P, Verhoeven E. , et al; ADSORB Trialists. Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg 2014; 48 (03) 285-291
  • 47 VIRTUE Registry Investigators. Mid-term outcomes and aortic remodelling after thoracic endovascular repair for acute, subacute, and chronic aortic dissection: the VIRTUE Registry. Eur J Vasc Endovasc Surg 2014; 48 (04) 363-371
  • 48 Akutsu K, Nejima J, Kiuchi K. , et al. Effects of the patent false lumen on the long-term outcome of type B acute aortic dissection. Eur J Cardiothorac Surg 2004; 26 (02) 359-366

Address for correspondence

Sanjiv Sharma, MD
Department of Cardiovascular Radiology and Endovascular Interventions
All India Institute of Medical Sciences, New Delhi
India   

  • References

  • 1 Elefteriades JA, Rizzo JA. Epidemiology, prevalence, incidence, trends. In: Elefteriades JA. , ed. Acute Aortic Disease. New York, NY: Informa Healthcare; 2008: 89-98
  • 2 Mehta RH, Bossone E, Evangelista A. , et al; International Registry of Acute Aortic Dissection Investigators. Acute type B aortic dissection in elderly patients: clinical features, outcomes, and simple risk stratification rule. Ann Thorac Surg 2004; 77 (05) 1622-1628 , discussion 1629
  • 3 Hagan PG, Nienaber CA, Isselbacher EM. , et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000; 283 (07) 897-903
  • 4 Cerna M, Kocher M, Thomas RP. Acute aorta, overview of acute CT findings and endovascular treatment options. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161 (01) 14-23
  • 5 Erbel R, Alfonso F, Boileau C. , et al; Task Force on Aortic Dissection, European Society of Cardiology. Diagnosis and management of aortic dissection. Eur Heart J 2001; 22 (18) 1642-1681
  • 6 Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55 (09) 841-857
  • 7 Yuan SM. Postpartum aortic dissection. Taiwan J Obstet Gynecol 2013; 52 (03) 318-322
  • 8 Manfredini R, Boari B, Gallerani M. , et al. Chronobiology of rupture and dissection of aortic aneurysms. J Vasc Surg 2004; 40 (02) 382-388
  • 9 Muhs BE, Vincken KL, van Prehn J. , et al. Dynamic cine-CT angiography for the evaluation of the thoracic aorta; insight in dynamic changes with implications for thoracic endograft treatment. Eur J Vasc Endovasc Surg 2006; 32 (05) 532-536
  • 10 Ueda T, Fleischmann D, Rubin GD, Dake MD, Sze DY. Imaging of the thoracic aorta before and after stent-graft repair of aneurysms and dissections. Semin Thorac Cardiovasc Surg 2008; 20 (04) 348-357
  • 11 Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part II: therapeutic management and follow-up. Circulation 2003; 108 (06) 772-778
  • 12 Criado FJ. Aortic dissection: a 250-year perspective. Tex Heart Inst J 2011; 38 (06) 694-700
  • 13 Onitsuka S, Akashi H, Tayama K. , et al. Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. Ann Thorac Surg 2004; 78 (04) 1268-1273
  • 14 Akin I, Kische S, Ince H, Nienaber CA. Indication, timing and results of endovascular treatment of type B dissection. Eur J Vasc Endovasc Surg 2009; 37 (03) 289-296
  • 15 Schneider AJ. Assessment of risk factors and surgical outcome. Surg Clin North Am 1983; 63 (05) 1113-1126
  • 16 Feldman M, Shah M, Elefteriades JA. Medical management of acute type A aortic dissection. Ann Thorac Cardiovasc Surg 2009; 15 (05) 286-293
  • 17 Walsh SR, Tang TY, Sadat U. , et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg 2008; 47 (05) 1094-1098
  • 18 Coady MA, Rizzo JA, Hammond GL, Kopf GS, Elefteriades JA. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg 1999; 67 (06) 1922-1926 , discussion 1953–1958
  • 19 Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med 1994; 331 (26) 1729-1734
  • 20 Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft placement in patients with type B aortic dissection: a meta-analysis in China. J Thorac Cardiovasc Surg 2009; 138 (04) 865-872
  • 21 Fann JI, Smith JA, Miller DC. , et al. Surgical management of aortic dissection during a 30-year period. Circulation 1995; 92 (9, Suppl): II113-II121
  • 22 Duarte JJ, Pontes JC, Benfatti RA, Ferrachini AL, Karakhanian WK, Razuk Filho A. Indication of endovascular treatment of type B aortic dissection—literature review. Rev Bras Cir Cardiovasc 2014; 29 (03) 396-401
  • 23 Jonker FH, Trimarchi S, Verhagen HJ, Moll FL, Sumpio BE, Muhs BE. Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. J Vasc Surg 2010; 51 (04) 1026-1032 , 1032.e1–1032.e2
  • 24 Nienaber CA, Rousseau H, Eggebrecht H. , et al; INSTEAD Trial. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation 2009; 120 (25) 2519-2528
  • 25 Parsa CJ, Schroder JN, Daneshmand MA, McCann RL, Hughes GC. Midterm results for endovascular repair of complicated acute and chronic type B aortic dissection. Ann Thorac Surg 2010; 89 (01) 97-102 , discussion 102–104
  • 26 Eggebrecht H, Nienaber CA, Neuhäuser M. , et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. Eur Heart J 2006; 27 (04) 489-498
  • 27 Evangelista A, Salas A, Ribera A. , et al. Long-term outcome of aortic dissection with patent false lumen: predictive role of entry tear size and location. Circulation 2012; 125 (25) 3133-3141
  • 28 Kitada S, Akutsu K, Tamori Y, Yoshimuta T, Hashimoto H, Takeshita S. Usefulness of fibrinogen/fibrin degradation product to predict poor one-year outcome of medically treated patients with acute type B aortic dissection. Am J Cardiol 2008; 101 (09) 1341-1344
  • 29 Luebke T, Brunkwall J, Type B. Type B aortic dissection: a review of prognostic factors and meta-analysis of treatment options. Aorta (Stamford) 2014; 2 (06) 265-278
  • 30 Jonker FH, Trimarchi S, Rampoldi V. , et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic expansion after acute type B aortic dissection. Ann Thorac Surg 2012; 94 (04) 1223-1229
  • 31 Tolenaar JL, van Keulen JW, Jonker FH. , et al. Morphologic predictors of aortic dilatation in type B aortic dissection. J Vasc Surg 2013; 58 (05) 1220-1225
  • 32 Clough RE, Albayati MA, Donati T, Taylor PR. Uncomplicated type B dissections: which patients should be treated? Lessons learned from the recent literature. J Cardiovasc Surg (Torino) 2014; 55 (02) (Suppl. 01) 145-150
  • 33 Grommes J, Greiner A, Bendermacher B. , et al. Risk factors for mortality and failure of conservative treatment after aortic type B dissection. J Thorac Cardiovasc Surg 2014; 148 (05) 2155-2160.e1
  • 34 Tsai TT, Evangelista A, Nienaber CA. , et al; International Registry of Acute Aortic Dissection. Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med 2007; 357 (04) 349-359
  • 35 Song JM, Kim SD, Kim JH. , et al. Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection. J Am Coll Cardiol 2007; 50 (08) 799-804
  • 36 Loewe C, Czerny M, Sodeck GH. , et al. A new mechanism by which an acute type B aortic dissection is primarily complicated, becomes complicated, or remains uncomplicated. Ann Thorac Surg 2012; 93 (04) 1215-1222
  • 37 Kitamura T, Torii S, Oka N. , et al. Key success factors for thoracic endovascular aortic repair for non-acute Stanford type B aortic dissection. Eur J Cardiothorac Surg 2014; 46 (03) 432-437 , discussion 437
  • 38 Fattori R, Cao P, De Rango P. , et al. Interdisciplinary expert consensus document on management of type B aortic dissection. J Am Coll Cardiol 2013; 61 (16) 1661-1678
  • 39 Fattori R, Tsai TT, Myrmel T. , et al. Complicated acute type B dissection: is surgery still the best option? A report from the International Registry of Acute Aortic Dissection. JACC Cardiovasc Interv 2008; 1 (04) 395-402
  • 40 Trimarchi S, Eagle KA, Nienaber CA. , et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Importance of refractory pain and hypertension in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2010; 122 (13) 1283-1289
  • 41 Leurs LJ, Bell R, Degrieck Y, Thomas S, Hobo R, Lundbom J. ; EUROSTAR; UK Thoracic Endograft Registry collaborators. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. J Vasc Surg 2004; 40 (04) 670-679 , discussion 679–680
  • 42 Fattori R, Montgomery D, Lovato L. , et al. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc Interv 2013; 6 (08) 876-882
  • 43 Zeeshan A, Woo EY, Bavaria JE. , et al. Thoracic endovascular aortic repair for acute complicated type B aortic dissection: superiority relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg 2010; 140 (6, Suppl): S109-S115 , discussion S142–S146
  • 44 Nienaber CA, Kische S, Rousseau H. , et al; INSTEAD-XL trial. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013; 6 (04) 407-416
  • 45 Garbade J, Jenniches M, Borger MA. , et al. Outcome of patients suffering from acute type B aortic dissection: a retrospective single-centre analysis of 135 consecutive patients. Eur J Cardiothorac Surg 2010; 38 (03) 285-292
  • 46 Brunkwall J, Kasprzak P, Verhoeven E. , et al; ADSORB Trialists. Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg 2014; 48 (03) 285-291
  • 47 VIRTUE Registry Investigators. Mid-term outcomes and aortic remodelling after thoracic endovascular repair for acute, subacute, and chronic aortic dissection: the VIRTUE Registry. Eur J Vasc Endovasc Surg 2014; 48 (04) 363-371
  • 48 Akutsu K, Nejima J, Kiuchi K. , et al. Effects of the patent false lumen on the long-term outcome of type B acute aortic dissection. Eur J Cardiothorac Surg 2004; 26 (02) 359-366